申请人:Farmitalia Carlo Erba, S.r.l.
公开号:US05204364A1
公开(公告)日:1993-04-20
The present invention relates to new N-imidazolyl and N-imidazolylmethyl derivatives of bicyclic compounds having the general formula (I) ##STR1## Wherein A is a .gtoreq.CR.sub.3 or >CHR.sub.3 group, in which R.sub.3 is hydrogen or C.sub.1 -C.sub.6 alkyl, or a >C.dbd.CR.sub.4 R.sub.5 group, in which each of R.sub.4 and R.sub.5 independently is hydrogen or C.sub.1 -C.sub.5 alkyl; Z is --CH.sub.2 --, --O-- or --S--; n is zero or 1; each of R and R.sub.1 is independently hydrogen or C.sub.1 -C.sub.6 alkyl; R.sub.2 is --COCH.sub.2 OH, --CH.sub.2 OR', --COOR', --CONR'R" or --CH.dbd.CH--COOR', in which each of R' and R" independently is hydrogen or C.sub.1 -C.sub.6 alkyl, and the pharmaceutically acceptable salts thereof; and wherein: a) when n is zero, then Z is --CH.sub.2 -- or --O--; whereas when n is one, then Z is --CH.sub.2 --, --O-- or --S--; b) when A is .gtoreq.CR.sub.3 or >CHR.sub.3 in which R.sub.3 is hydrogen, then n is one; and c) when, at the same time, A is >CHR.sub.3 in which R.sub.3 is hydrogen, Z is --CH.sub.2 --, n is one and R.sub.2 is --COOR' wherein R' is as defined above, then at least one of R and R.sub.1 is other than hydrogen, which are useful in the treatment of diseases related to an enhancement of TxA.sub.2 synthesis.
本发明涉及具有通式(I)的新的N-咪唑基和N-咪唑基甲基衍生物的双环化合物:
其中A是.gtoreq.CR.sub.3或>CHR.sub.3基团,其中R.sub.3是氢或C.sub.1 -C.sub.6烷基,或>C.dbd.CR.sub.4R.sub.5基团,其中R.sub.4和R.sub.5各自独立地是氢或C.sub.1 -C.sub.5烷基;Z是--CH.sub.2--,--O--或--S--;n为零或1;R和R.sub.1各自独立地是氢或C.sub.1 -C.sub.6烷基;R.sub.2是--COCH.sub.2OH,--CH.sub.2OR',--COOR',--CONR'R"或--CH.dbd.CH--COOR',其中R'和R"各自独立地是氢或C.sub.1 -C.sub.6烷基,以及其药学上可接受的盐;在以下情况下:a)当n为零时,Z为--CH.sub.2--或--O--;而当n为一时,Z为--CH.sub.2--,--O--或--S--;b)当A为.gtoreq.CR.sub.3或>CHR.sub.3且R.sub.3为氢时,n为一;和c)当同时A为>CHR.sub.3且R.sub.3为氢,Z为--CH.sub.2--,n为一且R.sub.2为--COOR',其中R'如上定义时,至少有一个R和R.sub.1不是氢,这些衍生物在治疗与TxA.sub.2合成增强相关的疾病方面是有用的。